Affect Therapeutics

Digital addiction treatment with contingency management

Affect Therapeutics

Digital addiction treatment with contingency management

Overview

Affect Therapeutics provides digital addiction recovery services that combine contingency management with therapy and medication. The platform is private, fully online, and accessible via secure video conferencing, removing the need to visit clinics. It uses financial incentives to reward healthy behaviors, helping users build new habits, and offers holistic support such as job search, housing guidance, and bill management to improve overall life circumstances. The business likely operates on a subscription or fee-for-service model to fund ongoing treatment and support. Compared to traditional clinics, the service emphasizes digital convenience, privacy, and integrated life-support, aiming to help people recover from addiction and improve their broader daily life.

Work here?Claim your company

About Affect Therapeutics

Simplify's Rating

Why Affect Therapeutics is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

Consumer SoftwareHealthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$49.1M

Headquarters

Tysons, VA

Founded

2020

Get referred to Affect Therapeutics

See people who can refer or advise you

Simplify's take

What believers are saying

Affect raised $26 million in September 2025, extending runway for expansion.
Its November 2025 Series B funded an AI-driven operating system and real-time clinical support.
The company now covers all 50 states on its website, expanding addressable patients.

What critics are saying

SAMHSA still disputes contingency management economics, capping reward levels and slowing payer adoption.
Mental-health app rivals like Big Health and Lyra sell broader employer bundles, pressuring pricing.
If reimbursement tightens after 2026, Affect’s insurance-driven model loses volume and cash flow.

What makes Affect Therapeutics unique

Affect bundles contingency management, therapy, psychiatry, and medication in one smartphone clinic.
It operates in 20 states and accepts Medicare, Medicaid, and commercial insurance.
Its 2026 app still advertises fully digital, private addiction care from home.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$49M

Below

Industry Average

Funded Over

5 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Below Average

Industry standards

Ind Avg. $35M

$30M

$45M

$65M

$100M

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Remote Work Options
Professional Development Budget

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

-1%

U.S. Securities and Exchange Commission

Oct 25th, 2026

EDGAR Filing Documents for 0001883067-21-000001

Behavioral Health Business

Nov 5th, 2025

Affect Therapeutics Raises $26M Funding

Affect Therapeutics, a digital mental health and addiction treatment provider, has raised $26M in a Series B funding round led by Allumia Ventures. The company offers therapy, medical support, and a gamified app for conditions like depression, PTSD, anxiety, OCD, and substance use disorders. It operates in several U.S. states and accepts major insurance plans. Previously, Affect Therapeutics raised $23M, including a $16M Series A in 2023.

Crunchbase

Jul 13th, 2023

Affect raises $16M as addiction-related financings hold strong

Affect Therapeutics, a provider of all-digital addiction treatment programs, raised $16 million in a Series A round led by Artis Ventures.

FinSMEs

Jul 12th, 2023

Affect Therapeutics Raises $16M In Series A Funding

Affect Therapeutics, a McLean, VA-based company providing addiction treatment for the digital age, raised $16M in Series A funding.The round was led by ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures. Stuart Peterson of ARTIS Ventures has joined the Board, and Dr. Imran Hamid of LifeArc Ventures joined the Board as an observer. The company intends to use the funds to enable national expansion, program expansion, and engineering innovation in the Affect app.Founded in 2020, Affect Therapeutics offers clinically intensive treatment that follows a scientifically-proven program supporting the entire recovery journey via a smartphone app for drug and alcohol addiction. The approach, based on the best research in the field including its own NIH-sponsored studies, combines experts at unlocking behavior change and motivation, with members receiving rewards for success in treatment, including engagement and provision of negative drug and alcohol screens. The company’s approach couples this type of cognitive behavioral therapy with counseling, medical oversight, and case management, delivering a comprehensive program based on decades of research.Affect currently holds outpatient treatment licenses in 20 states and aims to serve a majority of the U.S. population by the end of 2023

Yahoo Finance

Jul 12th, 2023

Delivering Next generation Addiction recovery, Affect Therapeutics raises $16 million in Series A funding led by ARTIS Ventures

Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures.

Recently Posted Jobs